126 related articles for article (PubMed ID: 7834335)
1. Early L-dopa treatment initially retards but later enhances dopamine receptor supersensitivity following unilateral dopamine denervation.
Carey RJ; Pinheiro-Carrera M; Tomaz C; Huston JP
Brain Res; 1994 Sep; 658(1-2):145-54. PubMed ID: 7834335
[TBL] [Abstract][Full Text] [Related]
2. Rapid reversal of denervation supersensitivity of dopamine D1 receptors by l-dopa or a novel dopamine D1 receptor agonist, A68930.
Britton DR; Kebabian JW; Curzon P
Eur J Pharmacol; 1991 Jul; 200(1):89-93. PubMed ID: 1685124
[TBL] [Abstract][Full Text] [Related]
3. Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.
Carey RJ
Brain Res; 1991 Dec; 568(1-2):205-14. PubMed ID: 1814568
[TBL] [Abstract][Full Text] [Related]
4. L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation.
Pinheiro-Carrera M; Tomaz C; Huston JP; Dai H; Carey RJ
Life Sci; 1994; 55(13):991-7. PubMed ID: 8084215
[TBL] [Abstract][Full Text] [Related]
5. NMDA antagonist effects on the development of L-dopa behavioral sensitization in rats.
Pinheiro-Carrera M; Tomaz C; Huston JP; Carey RJ
Behav Neurosci; 1995 Feb; 109(1):34-42. PubMed ID: 7734078
[TBL] [Abstract][Full Text] [Related]
6. 'Priming' enhances the relationship of striatal L-dopa concentration to behavior.
Pinheiro-Carrera M; Tomaz C; Huston JP; Dai H; Carey RJ
Neuroreport; 1994 Aug; 5(13):1665-9. PubMed ID: 7819543
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
9. 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
Bräutigam K; Sohr R; Morgenstern R
Behav Brain Res; 1994 Jul; 63(1):41-5. PubMed ID: 7945976
[TBL] [Abstract][Full Text] [Related]
10. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine.
Mura A; Jackson D; Manley MS; Young SJ; Groves PM
Brain Res; 1995 Dec; 704(1):51-60. PubMed ID: 8750961
[TBL] [Abstract][Full Text] [Related]
11. L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.
Ferre S; Casas M; Cobos A; Garcia C; Jane F; Grau JM
Psychopharmacology (Berl); 1987; 91(2):254-6. PubMed ID: 3107042
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum.
Lopez A; Muñoz A; Guerra MJ; Labandeira-Garcia JL
Neuroscience; 2001; 103(3):639-51. PubMed ID: 11274784
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and biochemical evidence for a different effect of repeated administration of L-dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors.
Rouillard C; Bédard PJ; Falardeau P; Dipaolo T
Neuropharmacology; 1987 Nov; 26(11):1601-6. PubMed ID: 3431663
[TBL] [Abstract][Full Text] [Related]
14. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
15. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
16. L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone.
Carey RJ; Pinheiro-Carrera M; Dai H; Tomaz C; Huston JP
Biol Psychiatry; 1995 Nov; 38(10):669-76. PubMed ID: 8555378
[TBL] [Abstract][Full Text] [Related]
17. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
Hall MD; Cooper DR; Fleminger S; Rupniak NM; Jenner P; Marsden CD
Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859
[TBL] [Abstract][Full Text] [Related]
18. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
19. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
[TBL] [Abstract][Full Text] [Related]
20. Biochemical alterations of dopamine receptor responses following chronic L-dopa therapy.
Wilner KD; Butler IJ; Seifert WE; Clement-Cormier YC
Biochem Pharmacol; 1980 Mar; 29(5):701-6. PubMed ID: 20227943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
